|
Age (years), median, range
|
52 (14–83)
|
52 (21–79)
|
0.705
|
|
Gender, no. (%)
|
|
Male
|
181 (66.3%)
|
27 (62.8%)
|
0.652
|
|
Female
|
92 (33.7%)
|
16 (37.2%)
| |
|
Median WBC (range), × 109/L
|
2.66 (0.27–13.47)
|
2.73 (1.10–12.00)
|
0.609
|
|
Median NE (range), × 109/L
|
0.99 (0.02–11.34)
|
0.85 (0.04–4.92)
|
0.794
|
|
Median HGB (range), g/L
|
69 (26–150)
|
67 (30–138)
|
0.291
|
|
Median PLT (range), × 109/L
|
53 (1–408)
|
47 (3–282)
|
0.911
|
|
MDS subtypes (WHO, 2016), no. (%)
|
0.243
|
|
MDS-SLD
|
11 (4.0%)
|
2 (4.7%)
| |
|
MDS-MLD
|
52 (19.1%)
|
4 (9.3%)
| |
|
MDS-RS-SLD
|
2 (0.7%)
|
2 (4.7%)
| |
|
MDS-RS-MLD
|
8 (2.9%)
|
3 (7.0%)
| |
|
MDS with isolated 5q-deletion
|
2 (0.7%)
|
0 (0.0%)
| |
|
MDS-EB-1
|
70 (25.7%)
|
10 (23.2%)
| |
|
MDS-EB-2
|
118 (43.2%)
|
21 (48.8%)
| |
|
MDS-U
|
10 (3.7%)
|
1 (2.3%)
| |
|
Cytogenetic
|
0.001
|
|
Normal karyotype
|
148 (54.2%)
|
12 (27.9%)
| |
|
Aberrant karyotype
|
125 (45.8%)
|
31 (72.1%)
| |
|
IPSS-R risk group, no. (%)
|
0.859
|
|
Very low
|
4 (1.5%)
|
0 (0.0%)
| |
|
Low
|
29 (10.6%)
|
5 (11.6%)
| |
|
Intermediate
|
65 (23.8%)
|
9 (20.9%)
| |
|
High
|
84 (30.8%)
|
12 (27.9%)
| |
|
Very high
|
91 (33.3%)
|
17 (39.6%)
| |
|
Treatment, no. (%)
|
0.170
|
|
Allogeneic HSCT
|
121 (44.3%)
|
20 (46.5%)
| |
|
Cytoreductive treatments without HSCT
|
90 (33.0%)
|
12 (27.9%)
| |
|
HMA
|
68 (25.0%)
|
10 (23.2%)
| |
|
Chemotherapy combined with HMA
|
20 (7.3%)
|
2 (4.7%)
| |
|
AML-like chemotherapy
|
2 (0.7%)
|
0 (0.0%)
| |
|
Immunoregulatory
|
11 (4.0%)
|
5 (11.6%)
| |
|
Supportive care
|
51 (18.7%)
|
6 (14.0%)
| |
|
Leukemia transformation, no. (%)
|
50 (18.3%)
|
8 (18.6%)
|
0.964
|
|
Median time from diagnosis to leukemia transformation, months (range)
|
12 (2–31)
|
7 (1–20)
|
0.043
|
